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Abstract
Background: The immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable
Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines
were evaluated among infants from Singapore and Malaysia, where PHiD-CV has been licensed.
Methods: In the primary vaccination phase, 298 infants from Singapore and 168 infants from Malaysia were randomised to
receive the Phase III Clinical (Clin) or the Commercial (Com) lot of PHiD-CV at 2, 3, and 5 months of age. In the booster
vaccination phase, 238 toddlers from Singapore received one dose of the PHiD-CV Commercial lot at 18–21 months of
age. Immune responses to pneumococcal polysaccharides were measured using 22F-inhibition enzyme-linked
immunosorbent assay (ELISA) and functional opsonophagocytic activity (OPA) assay and to protein D, using ELISA.
Results: Immune responses induced by primary vaccination with the PHiD-CV Commercial lot were non-inferior to the
Phase III Clinical lot in terms of adjusted antibody geometric mean concentration (GMC) ratios for each vaccine
pneumococcal serotype and protein D. For each vaccine pneumococcal serotype, ≥93.6% and ≥88.5% of infants from
Malaysia and Singapore had post-primary vaccination antibody concentrations ≥0.2 μg/mL and OPA titres ≥8, in the
Clin and Com groups, respectively. For each vaccine pneumococcal serotype, ≥60.8% and ≥98.2% of toddlers from
Singapore had pre- and post-booster antibody concentrations ≥0.2 μg/mL, in the Clin and Com groups, respectively. All
children, except one, had measurable anti-protein D antibodies and the primary and booster doses of the co-administered
vaccines were immunogenic. The incidence of each grade 3 solicited symptom was ≤11.1% in both study phases. No
serious adverse events considered causally related to vaccination were reported throughout the study.
Conclusions: PHiD-CV given as three-dose primary vaccination to infants in Singapore and Malaysia and booster
vaccination to toddlers in Singapore was shown to be immunogenic with a clinically acceptable-safety profile.
This study has been registered at www.clinicaltrials.gov NCT00808444 and NCT01119625.
Keywords: Pneumococcal conjugate vaccine, Immunogenicity, Safety, Non-typeable Haemophilus influenzae,
Infant, Toddler, Singapore, Malaysia
* Correspondence: fong_seng_lim@nhgp.com.sg
†Equal contributors
1National Healthcare Group Polyclinics, 3 Fusionopolis Link #03-08,
Nexus@one-north, Singapore 138543, Singapore
Full list of author information is available at the end of the article
© 2014 Lim et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Lim et al. BMC Infectious Diseases 2014, 14:530
http://www.biomedcentral.com/1471-2334/14/530
Background
Streptococcus pneumoniae is responsible for invasive dis-
eases, which cause significant morbidity and mortality
worldwide [1]. The incidence of invasive pneumococcal
disease (IPD) is especially high in Asia, where children
younger than 5 years old are the most severely affected
[2-5]. In Singapore, the incidence of IPD reached 15.2
per 100,000 children <5 years of age in 2008–2010; the
most common serotypes were serotypes 6B, 19A, 14,
and 23F [6]. In Malaysia, there is limited information on
the incidence of IPD, although a previous study sug-
gested that the incidence of pneumococcal meningitis
reached 8.6 per 100,000 children <5 years of age in
2004–2006 [7]. The most common serotypes in Malaysia
in 2008–2009 were serotypes 19F, 6B, 19A, and 14 [6,8].
In both countries, emergence of antimicrobial resistant
S. pneumoniae isolates is a major health concern [3,8-14].
Prevention of pneumococcal infections through vac-
cination remains the best strategy to reduce the inci-
dence of IPD. A 10-valent pneumococcal non-typeable
Haemophilus influenzae (NTHi) protein D conjugate
vaccine (PHiD-CV; Synflorix™, GlaxoSmithKline Vaccines),
which contains serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F,
and 23F, was licensed in Singapore in March 2010 and in
Malaysia in September 2009. PHiD-CV has been shown to
be immunogenic and well-tolerated when co-administered
with commonly used paediatric vaccines in infants and
toddlers [15-22]. Since eight of the ten pneumococcal sero-
types included in PHiD-CV are conjugated to NTHi pro-
tein D, this vaccine has the potential to provide additional
protection against NTHi diseases [23].
This study compared the immunogenicity, reactogeni-
city, and safety of three-dose primary vaccination with a
Phase III Clinical lot or a Commercial lot of PHiD-CV
co-administered with routine childhood vaccines in in-
fants from Singapore and Malaysia. The immunogenicity
and safety of a booster dose of the PHiD-CV Commer-
cial lot were also evaluated in toddlers from Singapore.
Methods
Study design
This Phase III study comprised a primary vaccination
phase conducted in three centres in Singapore and two
centres in Malaysia between January 2009 and November
2009, and a booster vaccination phase conducted in the
three Singaporean centres between July 2010 and February
2011. The booster vaccination phase did not encompass
Malaysia since PHiD-CV obtained registration in Malaysia
in September 2009 and booster vaccination could thus be
offered outside clinical trial settings.
In the primary vaccination phase, infants were rando-
mised (1:1) to two parallel groups to receive three doses
of the PHiD-CV Phase III Clinical (Clin group) or Com-
mercial lot (Com group) at 2, 3, and 5 months of age.
PHiD-CV was co-administered with diphtheria, tetanus,
acellular pertussis-hepatitis B virus-inactivated poliovirus,
and H. influenzae type b vaccine (DTPa-HBV-IPV/Hib) in
Malaysia at 2, 3, and 5 months of age and in Singapore at
2 and 5 months of age and with DTPa-IPV/Hib in
Singapore at 3 months of age. All infants received two
doses of a human rotavirus (HRV) vaccine at 2 and
3 months of age. The primary vaccination phase was
double-blinded.
In the booster vaccination phase, all toddlers from
Singapore received a booster dose of the PHiD-CV
Commercial lot co-administered with DTPa-IPV/Hib
at 18–21 months of age. Thus, the booster vaccination
phase was conducted in an open-label manner.
The study was conducted in accordance with Good Clin-
ical Practice guidelines and the Declaration of Helsinki.
The protocol and associated documents were reviewed
and approved by the Medical Research & Ethics Commit-
tee of the Ministry of Health in Malaysia and the Medical
Ethics Committee of University Malaya Medical Centre
and the Domain-Specific Review Board of the National
Healthcare Group in Singapore. Written informed consent
was obtained before enrolment from the parents or legally
acceptable representatives of each child. This study has
been registered at www.clinicaltrials.gov NCT00808444
and NCT01119625. A protocol summary is available at
http://www.gsk-clinicalstudyregister.com (GSK study IDs
111654 and 113266).
Study objectives
The primary objectives were to demonstrate the compar-
ability of the immune response induced by three-dose pri-
mary vaccination with the Commercial lot versus the
Phase III Clinical lots of PHiD-CV in infants from Malaysia
and Singapore, and to assess the persistence of the anti-
bodies induced by both PHiD-CV lots up to the booster
vaccination in toddlers from Singapore. Secondary objec-
tives included the evaluation of the immunogenicity, safety,
and reactogenicity of PHiD-CV and the co-administered
vaccines after primary and booster vaccinations.
Study participants
Eligible participants were healthy infants from Malaysia
and Singapore aged 6–12 weeks at the time of the first
vaccination, who were born after a gestation period of
between 36 and 42 weeks. For the booster vaccination
phase, eligible participants were healthy toddlers aged
18–21 months at the time of the booster vaccination,
who had received three PHiD-CV doses in the primary
vaccination phase in Singapore.
Children were excluded from participation if they were
concurrently participating in another clinical study; were
immunosuppressed; had used investigational products
within 30 days pre-vaccination; had previously received
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blood products; had previous vaccination against or his-
tory of diphtheria, tetanus, pertussis, poliomyelitis, hepa-
titis B, Hib, or pneumococcal disease; or had allergic
disease or reactions likely to be exacerbated by the vac-
cines, history of neurological disorders or seizures, major
congenital defects, or a serious chronic illness.
Vaccines
The Commercial and Phase III Clinical lots of PHiD-CV
had the same composition, which has been previously
described [21]. They were administered intramuscularly
in the right thigh in infants and the right deltoid or thigh
in toddlers. All co-administered vaccines were manufac-
tured by GlaxoSmithKline Vaccines. DTPa-IPV/Hib
(Infanrix™-IPV/Hib) and DTPa-HBV-IPV/Hib (Infanrix™
hexa) were administered intramuscularly in the left thigh
in infants and the left deltoid or thigh in toddlers. The
live attenuated HRV vaccine (Rotarix™) was administered
orally.
Immunogenicity assessment
Blood samples were collected one month post-primary
vaccination and before and one month after the booster
vaccination. Antibody concentrations against vaccine
pneumococcal serotypes and cross-reactive serotypes
were measured by 22F-inhibition enzyme-linked immuno-
sorbent assay (ELISA) as described previously (cut-off:
0.05 μg/mL) [24,25]. Percentages of children with antibody
concentrations ≥0.2 μg/mL were determined. Antibody
concentrations of 0.2 μg/mL measured by 22F-inhibition
ELISA are equivalent to antibody concentrations of
0.35 μg/mL measured by the World Health Organization
reference ELISA without 22F-inhibition, which is the
threshold used for comparisons of immune responses
induced by different pneumococcal conjugate vaccines
[25,26]. In the primary vaccination phase, opsonopha-
gocytic activity (OPA) was measured by a pneumococ-
cal killing assay using a HL 60 cell line (cut-off titre: 8)
[27,28]. Antibodies against NTHi protein D were measured
by an in-house ELISA using a recombinant non-lipidated
form of protein D as coating material. Anti-protein D anti-
bodies, which are bound to protein D antigens adsorbed
on polystyrene plates, are detected using an anti-human-
IgG peroxidase labelled antibody followed by the addition
of tetramethylbenzidine substrate. Anti-protein D antibody
concentrations were expressed in ELISA units per mL
(EL.U/mL), and the assay cut-off was 100 EL.U/mL.
Infants were sub-randomised (1:1) to two subsets for
the analysis of immune responses to co-administered
vaccines. Immune responses were measured by ELISA
[29-34], except for the three poliovirus types, which were
measured by a virus microneutralisation test [35]. All la-
boratory analyses were performed at GlaxoSmithKline
(Rixensart, Belgium) or in laboratories designated by
GlaxoSmithKline Vaccines. Upon discovery of an anti-
hepatitis B assay specificity issue, a risk was identified
that children whose post-vaccination titres were initially
measured between 10 and 100 mIU/mL might have been
informed of an incorrect seroprotection status. Retesting
was performed as an urgent precaution using Immulite™,
a commercial assay used for routine testing at Ghent
University Hospital, Belgium.
Safety and reactogenicity assessment
Solicited local (injection sites pain, redness, and swell-
ing) and general (irritability, drowsiness, fever [rectal/ax-
illary temperature ≥38.0°C/37.5°C], and loss of appetite)
symptoms and antipyretic use were recorded during a
four-day post-vaccination period. In the primary vaccin-
ation phase, vomiting and diarrhoea were also recorded
for four days post-vaccination. Unsolicited adverse events
(AEs) were recorded for 31 days post-vaccination. The in-
tensity of each symptom was graded on a three-grade
scale. Grade 3 was reported for pain if infants/toddlers
cried when the limbs were moved or if the limbs were
spontaneously painful; redness and swelling, if diame-
ters were >30 mm; fever, if rectal/axillary temperature
was >40.0°C/39.5°C; loss of appetite, if infants/toddlers
did not eat at all; irritability, if infants/toddlers cried
and could not be comforted; diarrhoea, if infants had ≥6
looser than normal stools/day; vomiting, if infants had ≥3
episodes/day; and all other AEs, if they prevented normal
activity.
Serious adverse events (SAEs) were recorded through-
out the study and were defined as events that were life-
threatening, required hospitalisation or prolongation of
hospitalisation, or resulted in disability, incapacity, or
death. As per protocol, all solicited local symptoms were
considered causally related to vaccination. Causality of
all other AEs was assessed by investigators.
Statistical analyses
Safety analyses were performed on the primary and booster
total vaccinated cohorts. Immunogenicity analyses were
performed on the primary and booster according-to-
protocol (ATP) immunogenicity cohorts and on the
ATP persistence cohort, which included all infants/
toddlers who met all eligibility criteria, complied with
protocol-defined procedures, and for whom antibody
assay results were available.
Antibody geometric mean concentrations (GMCs), OPA
geometric mean titres (GMTs), and percentages of infants/
toddlers with concentrations or titres above pre-specified
cut-offs/thresholds were calculated with 95% confidence
intervals (CIs). GMCs and GMTs were calculated by taking
the anti-log of the mean of the log antibody concentration/
titre transformations. Antibody concentrations/titres below
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assay cut-offs were given an arbitrary value of half the
cut-off.
Non-inferiority of the Commercial versus the Phase III
Clinical lot was demonstrated if the upper limit (UL) of
the two-sided 95% CI (calculated using an ANOVA
model [pooled variance] adjusting for multi-country ef-
fect) on adjusted GMC ratios (Clin over Com group) for
antibodies against vaccine pneumococcal serotypes and
protein D was below 2.
In the primary vaccination phase, the target sample
size was 460 enrolled infants to obtain ≥400 evaluable
infants. When comparing both PHiD-CV lots, 200 evalu-
able infants per group would provide at least 98% power
under equal mean or 85% power in case of 1.2-fold de-
crease in GMCs to show non-inferiority of the Commer-
cial lot compared to the Phase III Clinical lot with respect
to adjusted antibody GMC ratios for vaccine pneumococ-
cal serotypes and protein D. In the booster vaccination
phase, the target sample size was 298 enrolled toddlers,
taking into account the actual enrolment in the primary
vaccination phase in Singapore.
Incidences of solicited and unsolicited AEs were calcu-
lated with exact 95% CIs. SAEs and withdrawals due to
AEs were described in detail. Non-overlapping two-sided
95% CIs were used to highlight potential group differ-
ences, which should be interpreted with caution.
Statistical analyses were performed using Statistical
Analysis System (SAS® software, SAS Institute Inc., Cary,
NC, United States) version 9.2 and SDD (i.e. SAS Drug
and Development) web portal version 3.5.
Results
Study population
A total of 466 infants were enrolled and 464 infants
completed the primary vaccination phase (Figure 1). 238
toddlers from Singapore were included in the booster
vaccination phase and 231 toddlers completed the study.
The demographic characteristics of the infants included
in the primary ATP immunogenicity cohort were com-
parable in both groups and were consistent with those
of the toddlers from Singapore included in the booster
ATP immunogenicity cohort (Table 1).
Immunogenicity
Pneumococcal vaccine antigens
In the primary vaccination phase, immune responses in-
duced by the PHiD-CV Commercial lot were shown to
Figure 1 Trial profile. Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary
vaccination phase. Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination
phase. ClinCom= group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in
the booster vaccination phase. ComCom = group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the
Commercial lot of PHiD-CV in the booster vaccination phase.
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be non-inferior to those induced by the Phase III Clin-
ical lot (Figure 2; Additional file 1: Table S1).
One month post-primary vaccination, for each vaccine
pneumococcal serotype, ≥96.3% and ≥93.6% of infants
had antibody concentrations ≥0.2 μg/mL in the Clin and
Com groups, respectively (Table 2). Antibody GMCs for
serotypes 4 and 5 seemed higher in the Clin group. For
each vaccine pneumococcal serotype, percentages of in-
fants with OPA titres ≥8 were ≥95.6% in the Clin group,
except for serotype 1, and ≥96.6% in the Com group, ex-
cept for serotypes 1 and 6B (Table 3). OPA GMTs for
serotype 18C seemed higher in the Clin group.
For each vaccine pneumococcal serotype, ≥71.8%
and ≥60.8% of toddlers at pre-booster vaccination,
and ≥99.1% and ≥98.2% of toddlers one month post-booster
vaccination, had antibody concentrations ≥0.2 μg/mL in the
ClinCom and ComCom groups, respectively (Table 4).
One month post-primary vaccination, for cross-reactive
serotypes 6A and 19A, ≥60.6% and ≥54.6% of infants had
antibody concentrations ≥0.2 μg/mL (Table 2), and ≥85.5%
and ≥37.7% of infants had OPA titres ≥8, in the Clin-
Com and ComCom groups, respectively (Table 3). One
month post-booster vaccination, for each cross-reactive
serotype, ≥93.4% of toddlers reached antibody concentra-
tions ≥0.2 μg/mL (Table 4).
One month post-primary vaccination, ≥99.5% of in-
fants had measurable anti-protein D antibodies and
higher anti-protein D adjusted antibody GMCs were ob-
served in the Clin group (Figure 2). The anti-protein D
antibody seropositivity rates were 100% and 98.3% of
toddlers at pre-booster vaccination, and 100% and 99.1%
of toddlers at one month post-booster vaccination in the
ClinCom and ComCom groups, respectively (data not
shown).
Co-administered vaccine antigens
One month post-primary and post-booster vaccination,
all children were seroprotected against diphtheria, tet-
anus and poliovirus types 1, 2 and 3, and all infants were
seropositive for antibodies against the three pertussis an-
tigens and polyribosylribitol phosphate from Hib. All in-
fants except one were seroprotected against hepatitis B
surface antigen (HBs) at one month post-primary vac-
cination. Three children had anti-HBs antibody concen-
trations which were initially measured between 10 and
100 mIU/mL. Out of these 3 children, upon retesting
Table 1 Demographic characteristics of the study participants (primary and booster ATP immunogenicity cohorts)
Primary vaccination phase Clin group Com group
N = 219 N = 218
Age Mean age ± SD (weeks) 7.3 ± 1.35 7.3 ± 1.31
Age range (weeks) 6–11 6–11
Gender Female n (%) 108 (49.3) 95 (43.6)
Male n (%) 111 (50.7) 123 (56.4)
Race Asian – South East Asian heritage n (%) 217 (99.1) 217 (99.5)
Asian – Central/South Asian heritage n (%) 1 (0.5) 0 (0.0)
Asian – East Asian heritage n (%) 1 (0.5) 1 (0.5)
Booster vaccination phase ClinCom group ClinCom group
N = 115 N = 116
Age Mean age ± SD (months) 18.8 ± 0.84 18.9 ± 0.85
Age range (months) 18–21 18–21
Gender Female n (%) 59 (51.3) 48 (41.4)
Male n (%) 56 (48.7) 68 (58.6)
Race Asian – South East Asian heritage n (%) 114 (99.1) 115 (99.1)
Asian – East Asian heritage n (%) 1 (0.9) 1 (0.9)
ATP = according to protocol.
Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase.
Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase.
ClinCom = group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster
vaccination phase.
ComCom = group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster
vaccination phase.
N = number of participants.
n (%) = number (percentage) of participants with the specified characteristic.
SD = standard deviation.
Range =minimum – maximum.
Lim et al. BMC Infectious Diseases 2014, 14:530 Page 5 of 13
http://www.biomedcentral.com/1471-2334/14/530
using Immulite™, one was found to be seroprotected
while the other 2 had anti-HBs antibody concentra-
tions <10 mIU/mL. This was further followed up by
investigators and one child was subsequently re-vaccinated.
Efforts to reach the other child for re-vaccination were un-
successful. Three months after the second dose of the HRV
vaccine, ≥81.9% of infants were seropositive for anti-HRV
antibodies (data not shown).
Safety
In the primary vaccination phase, pain and diarrhoea were
the most common overall per dose Grade 3 solicited local
and general symptoms, respectively (Figure 3a). Diarrhoea
was the most common Grade 3 solicited general symptom
considered causally related to vaccination (following
15/698 and 22/698 doses in Clin and Com groups, re-
spectively). Antipyretic use was reported after 296/698
and 276/699 doses, and antipyretics were given prophylac-
tically after 45/698 and 41/699 doses, in the Clin and Com
groups, respectively. During 31 days post-vaccination,
113/698 and 119/699 doses were followed by at least one
unsolicited AE in the Clin and Com groups, respectively.
The most frequently reported unsolicited AEs were
upper respiratory tract infections (35/698 doses) and
cough (10/698 doses) in the Clin group, and upper re-
spiratory tract infections (42/699 doses) and pyrexia
(7/699 doses) in the Com group. No Grade 3 unsolicited
AEs were considered causally related to vaccination. SAEs
were reported in 18 and 7 infants in the Clin and Com
groups, respectively; none were considered causally re-
lated to vaccination and none were fatal.
In the booster vaccination phase, the most common
Grade 3 solicited local and general symptoms were pain
and irritability, respectively (Figure 3b). Grade 3 solicited
general symptoms considered causally related to vaccin-
ation were reported in ≤4.3% of toddlers, including
Grade 3 fever in one toddler (0.9%) in each group. Anti-
pyretic use was reported in 50/118 and 66/120 toddlers,
and prophylactic antipyretics use in 7/118 and 4/120
toddlers, in the ClinCom and ComCom groups, respect-
ively. Unsolicited AEs were reported in 18/118 and 25/
120 toddlers in the ClinCom and ComCom groups, re-
spectively. The most frequently reported unsolicited AEs
were rhinorrhea (7/118 toddlers) and cough (5/118 tod-
dlers) in the ClinCom group, and upper respiratory tract
infections (6/120 toddlers) and rhinorrhea and pyrexia
(each in 5/120 toddlers) in the ComCom group. One
Grade 3 unsolicited AE considered causally related to
vaccination (urticaria) was reported in the ComCom
group. Four toddlers in the ComCom group reported
SAEs; none were considered causally related to vaccin-
ation and none were fatal.
Discussion
Three primary doses of PHiD-CV given to 2-, 3-, and
5-month-old infants from Malaysia and Singapore were
Figure 2 Adjusted antibody GMC ratios between the Clin and the Com groups for the 10 vaccine pneumococcal serotypes and protein
D at one month post-primary vaccination (primary ATP immunogenicity cohort). Clin = group of infants from Malaysia and Singapore who
received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase. Com = group of infants from Malaysia and Singapore who received
the Commercial lot of PHiD-CV in the primary vaccination phase. Adjusted antibody GMC ratio = ratio of the geometric mean concentration at
one month post-primary vaccination adjusted for country (pooled variance; Clin over Com group). PD = protein D. 95% CI = 95% confidence
intervals (represented by the error bars). *Immunological non-inferiority was demonstrated if the upper limit of the 95% confidence interval
of the adjusted antibody GMC ratio (Clin over Com) was below 2.0.
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shown to be immunogenic with a clinically acceptable
safety profile. Non-inferiority of the immunogenicity of
the PHiD-CV Commercial versus the Phase III Clinical lot
was demonstrated for each vaccine pneumococcal sero-
type and protein D, although antibody GMCs for sero-
types 4 and 5 and protein D, and OPA GMTs for serotype
18C, seemed higher in infants who received the Phase III
Clinical lot. Nonetheless, as percentages of infants reach-
ing threshold antibody concentrations and OPA titres
for vaccine antigens were high and comparable in both
groups, the observed differences in immunogenicity
may be of limited clinical relevance. For each vaccine
pneumococcal serotype, post-primary vaccination anti-
body GMCs seemed in line with those previously mea-
sured in Korea and Taiwan [16,19], and higher than in
Europe [15,18,21]. Although it remains unclear why
the magnitude of immune responses to pneumococcal
conjugate vaccines varies in different populations,
plausible explanations include genetic factors, early ex-
posure to S. pneumoniae, or nasopharyngeal carriage
of pneumococcal serotypes [36]. Pre-vaccination anti-
body concentration, which is influenced by waning
Table 2 Immune responses to pneumococcal polysaccharides at one month post-primary vaccination (primary ATP
immunogenicity cohort): 22F-ELISA
Clin group Com group
N
% ≥0.2 μg/mL GMC
N
% ≥0.2 μg/mL GMC






























































(54.9 – 68.1) (0.23 – 0.31) (47.7 – 61.3) (0.20 – 0.27)
ATP = according to protocol.
Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase.
Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase.
N = number of infants with available results.
95% CI = 95% confidence interval.
GMC = geometric mean concentration.
% = percentage of infants with antibody concentrations or OPA titres above the specified cut-off.
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maternal antibodies and increasing adaptive immunity
due to early exposure to S. pneumoniae, in Asian chil-
dren was evaluated in a previous study conducted in
Taiwan, where for each vaccine pneumococcal serotype
the percentage of children with pre-vaccination anti-
body concentrations ≥0.2 μg/ml ranged from 11.5% to
42.5%, except serotype 14 (61%) [19]. Vaccine efficacy
and effectiveness of pneumococcal conjugate vaccines
have been demonstrated in various countries, hence
clinical relevance of population differences remains
unknown [37-42].
For each vaccine pneumococcal serotype, antibody
GMCs calculated before the booster dose administration
were lower than those measured one month post-primary
vaccination, but ≥60.8% of toddlers from Singapore had
pre-booster antibody concentrations ≥0.2 μg/mL. The
booster dose of the PHiD-CV Commercial lot induced
a robust immune response; virtually all toddlers reached
Table 3 Immune responses to pneumococcal polysaccharides at one month post-primary vaccination (primary ATP
immunogenicity cohort): OPA



































































(35.1 – 49.4) (13.7 – 23.8) (30.9 – 44.8) (11.5 – 19.8)
ATP = according to protocol.
OPA = opsonophagocytic activity.
Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase.
Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase.
N = number of infants with available results.
95% CI = 95% confidence interval.
GMT = geometric mean titre.
% = percentage of infants with antibody concentrations or OPA titres above the specified cut-off.
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Table 4 Pre- and post-booster immune response to pneumococcal polysaccharides (ATP persistence and booster ATP immunogenicity cohorts)
ClinCom group ComCom group
Pre-booster dose Post-booster dose Pre-booster dose Post-booster dose
N % ≥0.2 μg/mL GMC N % ≥0.2 μg/mL GMC N % ≥0.2 μg/mL GMC N % ≥0.2 μg/mL GMC
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Vaccine serotypes
Serotype 1 111 85.6 0.48 107 100 7.14 112 75.0 0.35 111 100 6.29
(77.6 – 91.5) (0.40 – 0.57) (96.6 – 100) (6.12 – 8.32) (65.9 – 82.7) (0.30 – 0.41) (96.7 – 100) (5.38 – 7.35)
Serotype 4 107 86.9 0.56 106 100 7.53 106 82.1 0.48 109 100 7.43
(79.0 – 92.7) (0.48 – 0.67) (96.6 – 100) (6.44 – 8.80) (73.4 – 88.8) (0.40 – 0.58) (96.7 – 100) (6.33 – 8.71)
Serotype 5 103 92.2 0.76 106 100 7.91 103 91.3 0.54 108 100 7.16
(85.3 – 96.6) (0.65 – 0.89) (96.6 – 100) (6.91 – 9.06) (84.1 – 95.9) (0.47 – 0.63) (96.6 – 100) (6.25 – 8.20)
Serotype 6B 103 71.8 0.34 106 100 3.30 102 60.8 0.32 109 98.2 3.12
(62.1 – 80.3) (0.29 – 0.40) (96.6 – 100) (2.85 – 3.81) (50.6 – 70.3) (0.25 – 0.41) (93.5 – 99.8) (2.59 – 3.76)
Serotype 7F 104 95.2 0.88 106 100 9.02 105 96.2 0.91 109 100 9.25
(89.1 – 98.4) (0.75 – 1.03) (96.6 – 100) (7.77 – 10.47) (90.5 – 99.0) (0.78 – 1.07) (96.7 – 100) (8.04 – 10.64)
Serotype 9V 105 98.1 0.90 107 100 9.36 102 94.1 0.73 109 100 10.42
(93.3 – 99.8) (0.77 – 1.06) (96.6 – 100) (8.15 – 10.75) (87.6 – 97.8) (0.62 – 0.85) (96.7 – 100) (8.94 – 12.14)
Serotype 14 105 93.3 1.06 106 100 13.03 100 93.0 0.91 106 100 13.28
(86.7 – 97.3) (0.86 – 1.31) (96.6 – 100) (10.95 – 15.50) (86.1 – 97.1) (0.75 – 1.11) (96.6 – 100) (11.06 – 15.95)
Serotype 18C 109 92.7 0.83 106 100 19.80 108 92.6 0.78 108 100 24.19
(86.0 – 96.8) (0.69 – 1.01) (96.6 – 100) (17.02 – 23.03) (85.9 – 96.7) (0.65 – 0.93) (96.6 – 100) (20.66 – 28.33)
Serotype 19F 103 98.1 1.10 106 100 19.68 103 99.0 0.96 108 100 20.55
(93.2 – 99.8) (0.87 – 1.40) (96.6 – 100) (17.22 – 22.51) (94.7 – 100) (0.82 – 1.13) (96.6 – 100) (17.62 – 23.98)
Serotype 23F 108 83.3 0.66 107 99.1 7.19 106 79.2 0.47 109 100 6.83
(74.9 – 89.8) (0.51 – 0.84) (94.9 – 100) (5.94 – 8.71) (70.3 – 86.5) (0.38 – 0.58) (96.7 – 100) (5.77 – 8.07)
Cross-reactive serotypes
Serotype 6A 109 53.2 0.23 106 99.1 2.13 111 45.0 0.21 108 97.2 1.99
(43.4 – 62.8) (0.18 – 0.28) (94.9 – 100) (1.70 – 2.66) (35.6 – 54.8) (0.16 – 0.26) (92.1 – 99.4) (1.60 – 2.49)
Serotype 19A 112 49.1 0.18 106 93.4 2.13 109 46.8 0.19 109 96.3 2.96
(39.5 – 58.7) (0.14 – 0.22) (86.9 – 97.3) (1.65 – 2.76) (37.2 – 56.6) (0.15 – 0.24) (90.9 – 99.0) (2.26 – 3.87)
ClinCom = group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
ComCom = group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
N = number of participants with available results.
95% CI = 95% confidence interval.
% = percentage of infants with antibody concentrations above the specified cut-off.



















antibody concentrations ≥0.2 μg/mL one month post-
booster vaccination and antibody concentrations were
higher than those measured post-primary vaccination,
which suggested that primary vaccination of infants with
PHiD-CV induced immunological memory [15,16,18,21].
Primary vaccination with either vaccine lot and booster
vaccination with the PHiD-CV Commercial lot induced
immune responses against cross-reactive serotypes 6A
and 19A. Some functional OPA responses for cross-
reactive serotype 19A were observed following primary
PHiD-CV vaccination, in-line with previous studies
[15,16,18,21]. However, the level of protection against
serotype 19A conferred by the immune response induced
by PHiD-CV should be further determined [43,44].
Both PHiD-CV lots induced antibodies against the NTHi
protein D carrier, which could potentially provide protec-
tion against disease caused by NTHi. Although a clear cor-
relation between efficacy and anti-protein D antibody
concentrations has not been established, efficacy trials with
the predecessor 11-valent NTHi protein D-conjugated
vaccine and PHiD-CV have suggested that the protein
D carrier contributed to the induction of protection
against acute otitis media due to NTHi [45,46]. The
co-administered vaccines given simultaneously with pri-
mary or booster doses of PHiD-CV were also immuno-
genic. This is consistent with other studies and suggests
that no clinically relevant interference occurred between
PHiD-CV and HRV or DTPa-based vaccines [17,19].
No SAEs considered causally related to vaccination
and no fatal SAEs were reported throughout the study.
The reactogenicity and safety profiles of the Commercial
and the Phase III Clinical lots of PHiD-CV were com-
parable and clinically acceptable, in line with previous
studies [20].
The primary vaccination phase was powered to demon-
strate the primary objectives. Other comparisons should
be considered cautiously, since there was no adjustment
for multiple comparisons of the various endpoints. The
clinical relevance of the observed differences remains un-
known, especially for antigens with no correlate of
Figure 3 Solicited symptoms following (a) primary vaccination (overall/dose; primary TVC) and (b) booster dose (booster TVC). TVC = total
vaccinated cohort. Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary
vaccination phase. Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination
phase. ClinCom= group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in
the booster vaccination phase. ComCom= group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the
Commercial lot of PHiD-CV in the booster vaccination phase. Error bars represent 95% confidence intervals. Solicited symptoms are recorded
during 4-days post-vaccination.
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protection. The booster vaccination phase was also limited
by its open design.
Conclusions
This study showed that different lots of PHiD-CV were
immunogenic with a clinically acceptable safety profile
when given as 3-dose primary vaccination in 2-, 3- and
5-month-old infants from Malaysia and Singapore. A
booster dose of the PHiD-CV Commercial lot induced
a robust immune response in 18–21 month-old tod-
dlers from Singapore. Both PHiD-CV lots were adminis-
tered with other paediatric vaccines without compromising
their immune response.
Synflorix, Infanrix-IPV/Hib, and Infanrix hexa are
trademarks of the GlaxoSmithKline group of companies.
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